Full Breakdown
FDA Approves Bemotrizinol, First New Sunscreen Ingredient in Over Two Decades
6/12/2026, 7:58:43 AM
FDA Approval Marks a Milestone in Sun Protection
On June 9, 2026 the U.S. Food and Drug Administration (FDA) classified the chemical filter bemotrizinol—also known as BEMT, Tinosorb S, or PARSOL Shield—as “generally recognized as safe and effective” (GRASE) for use in sunscreens for adults and children six months and older. The decision ends a 20-plus-year period without any new sunscreen active ingredient in the United States.
Background & Context
U.S. sunscreen formulations have relied on a fixed menu of roughly 16 approved filters, most of which protect either UVA or UVB but not both. Existing chemical filters degrade under sunlight, requiring frequent reapplication, while mineral filters (zinc oxide, titanium dioxide) block both spectra but often leave a white cast. International markets have used bemotrizinol for decades, offering broad-spectrum protection and high photostability. The FDA’s drug-like review process has historically slowed the introduction of newer filters.
Key Figures & Groups
- Dermatologists: Gary Goldenberg, Adam Friedman (George Washington University), Michele Green (New York), Helen He (New York), Lauren Taglia (Northwestern Medicine), Debra Jaliman (Mount Sinai), Jennifer Stein (NYU Langone), Anthony M. Rossi (Memorial Sloan Kettering), Abigail Waldman (Boston).
- Organizations: FDA, DSM Nutritional Products/DSM-Firmenich (ingredient manufacturer), Environmental Working Group, American Academy of Dermatology, Skin Cancer Foundation, AARP, American Cancer Society.
Data & Statistics
- UVA accounts for ~95 % of UV radiation reaching Earth; UVB makes up the remaining ~5 % (source 1).
- UVA contributes to premature aging and skin-cancer risk; UVB causes sunburn and is the leading cause of skin cancer (source 1).
- One in five Americans will be diagnosed with melanoma; 23 die daily (source 9).
- Approximately 90 % of non-melanoma skin cancers are linked to UV exposure (source 11).
- FDA safety data: minimal systemic absorption, a two-year animal study showed no cancer, and multigenerational studies found no reproductive toxicity (source 2).
Official Statements & Responses
The FDA’s GRASE designation follows extensive human safety studies, animal toxicology, photostability testing, and an environmental assessment. DSM will market the first BEMT-based product under the brand “Parsol Shield” with exclusive U.S. rights for 18 months; broader availability is expected later in 2026. The Environmental Working Group hailed the move as “a great day for American consumers” (source 8). The American Academy of Dermatology called the approval “an important public health step” (source 9).
Criticism & Opposition
Several experts caution that BEMT does not eliminate the need for regular reapplication, especially during water exposure or heavy sweating (source 4). Environmental data on long-term marine impact remain limited, and the term “reef-safe” lacks regulatory definition (source 4). Thus, BEMT should complement, not replace, other sun-protection measures such as shade, clothing, and SPF 30+ sunscreen.
Conflicting Reports & Gaps
Sources differ on the extent to which BEMT prolongs protection. Some dermatologists claim its photostability may reduce reapplication frequency (source 1, 6), while others note that formulation factors and activity level still dictate reapplication every 90 minutes (source 4). Comprehensive field studies on real-world durability are pending.
Verbatim Quotes
- “This is excellent news and long overdue,” — Gary Goldenberg, dermatologist (source 1)
- “This is a meaningful step forward,” — Adam Friedman, MD, chair of Dermatology, George Washington University (source 6)
- “This is a great day for American consumers and everyone who has fought to improve sunscreen options and close the UVA protection gap in U.S. sunscreens,” — David Andrews, chief science officer, Environmental Working Group (source 8)
- “It's also referred to as Tinosorb S and PARSOL Shield. So, multiple names for the same ingredient, but it's broad spectrum, meaning it covers the UVA and UVB wavelengths of light,” — Lauren Taglia, dermatologist, Northwestern Medicine (source 9)
- “chemical filter does that on its own.” — WXYZ reporter quoting experts (source 14)
What’s Next
Parsol Shield is slated for U.S. retail by the end of 2026. After the 18-month exclusivity period, other manufacturers may incorporate bemotrizinol into their formulations, potentially expanding the range of lightweight, photostable sunscreens. Dermatologists anticipate that broader ingredient options could improve consumer adherence and, over time, reduce skin-cancer incidence.
